Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Microbiome Diagnostics Market, by Application
1.4.2 North America Microbiome Diagnostics Market, by Product
1.4.3 North America Microbiome Diagnostics Market, by Sample
1.4.4 North America Microbiome Diagnostics Market, by Technology
1.4.5 North America Microbiome Diagnostics Market, by End User
1.4.6 North America Microbiome Diagnostics Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Opportunities
3.2.3 Market Restraints
3.2.4 Market Challenges
3.3 Porter Five Forces Analysis
Chapter 4. Strategies Deployed in Microbiome Diagnostics Market
Chapter 5. North America Microbiome Diagnostics Market by Application
5.1 North America Disease Diagnostics Market by Region
5.2 North America Microbiome Diagnostics Market by Disease Diagnostics Type
5.2.1 North America Gastrointestinal Disorders Market by Country
5.2.2 North America Metabolic Diseases Market by Country
5.2.3 North America Others Market by Country
5.3 North America Research Application Market by Region
Chapter 6. North America Microbiome Diagnostics Market by Product
6.1 North America Reagents & Kits Market by Country
6.2 North America Instruments Market by Country
Chapter 7. North America Microbiome Diagnostics Market by Sample
7.1 North America Fecal Market by Country
7.2 North America Saliva Market by Country
7.3 North America Skin Market by Country
7.4 North America Others Market by Country
Chapter 8. North America Microbiome Diagnostics Market by Technology
8.1 North America 16S rRNA Sequencing Market by Country
8.2 North America Shot Gun Metagenomics Market by Country
8.3 North America Metatranscriptomics Market by Country
8.4 North America Others Market by Country
Chapter 9. North America Microbiome Diagnostics Market by End User
9.1 North America Hospitals Market by Country
9.2 North America Academic & Research Institutes Market by Country
9.3 North America Biotechnology & Pharmaceutical Companies Market by Country
Chapter 10. North America Microbiome Diagnostics Market by Country
10.1 US Microbiome Diagnostics Market
10.1.1 US Microbiome Diagnostics Market by Application
10.1.1.1 US Microbiome Diagnostics Market by Disease Diagnostics Type
10.1.2 US Microbiome Diagnostics Market by Product
10.1.3 US Microbiome Diagnostics Market by Sample
10.1.4 US Microbiome Diagnostics Market by Technology
10.1.5 US Microbiome Diagnostics Market by End User
10.2 Canada Microbiome Diagnostics Market
10.2.1 Canada Microbiome Diagnostics Market by Application
10.2.1.1 Canada Microbiome Diagnostics Market by Disease Diagnostics Type
10.2.2 Canada Microbiome Diagnostics Market by Product
10.2.3 Canada Microbiome Diagnostics Market by Sample
10.2.4 Canada Microbiome Diagnostics Market by Technology
10.2.5 Canada Microbiome Diagnostics Market by End User
10.3 Mexico Microbiome Diagnostics Market
10.3.1 Mexico Microbiome Diagnostics Market by Application
10.3.1.1 Mexico Microbiome Diagnostics Market by Disease Diagnostics Type
10.3.2 Mexico Microbiome Diagnostics Market by Product
10.3.3 Mexico Microbiome Diagnostics Market by Sample
10.3.4 Mexico Microbiome Diagnostics Market by Technology
10.3.5 Mexico Microbiome Diagnostics Market by End User
10.4 Rest of North America Microbiome Diagnostics Market
10.4.1 Rest of North America Microbiome Diagnostics Market by Application
10.4.1.1 Rest of North America Microbiome Diagnostics Market by Disease Diagnostics Type
10.4.2 Rest of North America Microbiome Diagnostics Market by Product
10.4.3 Rest of North America Microbiome Diagnostics Market by Sample
10.4.4 Rest of North America Microbiome Diagnostics Market by Technology
10.4.5 Rest of North America Microbiome Diagnostics Market by End User
Chapter 11. Company Profiles
11.1 Illumina, Inc.
11.1.1 Company Overview
11.1.2 Financial Analysis
11.1.3 Regional Analysis
11.1.4 Research & Development Expense
11.1.5 Recent strategies and developments:
11.1.5.1 Partnerships, Collaborations, and Agreements:
11.1.6 SWOT Analysis
11.2 Becton, Dickinson, and Company
11.2.1 Company Overview
11.2.2 Financial Analysis
11.2.3 Segmental and Regional Analysis
11.2.4 Research & Development Expense
11.2.5 Recent strategies and developments:
11.2.5.1 Product Launches and Product Expansions:
11.2.5.2 Trails and Approvals:
11.2.6 SWOT Analysis
11.3 Genetic Analysis AS
11.3.1 Company Overview
11.3.2 Financial Analysis
11.3.3 Regional Analysis
11.3.4 Recent strategies and developments:
11.3.4.1 Partnerships, Collaborations, and Agreements:
11.4 Microba Life Sciences Limited
11.4.1 Company Overview
11.4.2 Financial Analysis
11.4.3 Regional Analysis
11.4.4 Research & Development Expenses
11.4.5 Recent strategies and developments:
11.4.5.1 Partnerships, Collaborations, and Agreements:
11.4.5.2 Product Launches and Product Expansions:
11.5 BioMe Oxford Ltd
11.5.1 Company Overview
11.5.2 Recent strategies and developments:
11.5.2.1 Partnerships, Collaborations, and Agreements:
11.6 Viome Life Sciences, Inc.
11.6.1 Company Overview
11.6.2 Recent strategies and developments:
11.6.2.1 Product Launches and Product Expansions:
11.6.2.2 Acquisition and Mergers:
11.7 GoodGut S.L.U. (HIPRA, S.A.)
11.7.1 Company Overview
11.8 Sun Genomics
11.8.1 Company Overview
11.9 Origin Sciences Limited
11.9.1 Company Overview
11.10. Decode Age
11.10.1 Company Overview
Unique Offerings 